Dr Nick Cammack is Senior Vice-President and Head, Medicines Development Campus for Diseases of the Developing World at GlaxoSmithKline (GSK) in Tres Cantos, Spain. He is responsible for the discovery and development of medicines to treat some of the most devastating neglected diseases including malaria, tuberculosis, Chagas disease, and Leishmaniasis. GSK are committed to achieving these objectives through an open and innovative approach to collaboration with many organizations such as Medicines for Malaria Venture, Global Alliance for TB, Wellcome Trust, and Bill & Melinda Gates Foundation. In addition, Nick has led the establishment and implementation of the Tres Cantos Open Lab Foundation – a not-for-profit foundation that supports academic scientists to visit GSK in Spain to pursue their own drug discovery ideas. This effort is a first for the pharma industry and is widely viewed as a bold, innovative step in neglected tropical disease drug discovery.

Prior to joining GSK, Dr Cammack was Global Head of the Virology Disease Biology Area at Hoffmann La Roche in Palo Alto, California where he was instrumental in the initiation and implementation of many significant external partnerships – the three-way Roche-Pharmasset-InterMune partnership was the first to conduct and demonstrate antiviral activity of an interferon-free combination of two small molecules for the treatment of Hepatitis C. Dr Cammack has also contributed to the discovery and development of three anti-HIV medicines and whilst at Roche where he was Head of the HIV Disease Area, he lead the Roche-Trimeris Virology Team resulting in the successful launch of the novel anti-HIV medicine, Fuzeon. He completed training at Leeds University and was a MRC Fellowship recipient at the London School of Hygiene and Tropical Medicine.